InvestSMART

Cleo Diagnostics Ltd (ASX: COV) - Share Price

Current share price for COV : $0.260 0.015 (6.12%)+

Cleo Diagnostics Ltd's current share price is $0.26. This constitutes a share price movement of -10.34% when compared to its closing share price of $0.29 seven days ago. Relative to today's opening stock price, the COV stock price is up 0.015 or 6.12%.

COV General Information +

ASX Code COV
Website N/A
Industry/Sector Health Care Equipment
Market Cap ($M) 35
COV Share Price $0.260
Day High $0.260
Day Low $0.245
Last Close $0.245
COV Share Price Movement $0.02 ( 6.12% )
Prices as at 16:21, 20 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Cleo Diagnostics Ltd (COV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Cleo Diagnostics Ltd (COV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cleo Diagnostics Ltd (COV) price-sensitive announcements

COV - CLEO Advances Toward Clinical Validation
Cleo Diagnostics Ltd announced that it has established the U.S. laboratory infrastructure
Cleo Diagnostics Ltd (COV)
12 Nov 2026 | 9:02 AM
COV - Quarterly activities and cashflow report
Cleo Diagnostics Ltd’s September 2026 Quarterly Activities and Cashflow Report outlines pr
Cleo Diagnostics Ltd (COV)
30 Oct 2026 | 4:11 PM
COV - CLEO Screening Test Meets Rigorous Performance Targets
Cleo Diagnostics Ltd announced that its prototype ovarian cancer screening test met or exc
Cleo Diagnostics Ltd (COV)
21 Oct 2026 | 9:03 AM
COV - CLEO Commences Analytical Validation Ahead of FDA Submission
Cleo Diagnostics Ltd announced that it has commenced Analytical Validation (AV) for its Pr
Cleo Diagnostics Ltd (COV)
13 Oct 2026 | 8:50 AM

Cleo Diagnostics Ltd (COV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
Health Care $36 CLEO Advances Toward Clinical Validation 12 Nov 2026 9:02AM $0.285 $0.260 fallen by 8.77%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
Health Care $36 Quarterly activities and cashflow report 30 Oct 2026 4:11PM $0.295 $0.260 fallen by 11.86%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
Health Care $36 CLEO Screening Test Meets Rigorous Performance Targets 21 Oct 2026 9:03AM $0.305 $0.260 fallen by 14.75%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
Health Care $36 CLEO Commences Analytical Validation Ahead of FDA Submission 13 Oct 2026 8:50AM $0.350 $0.260 fallen by 25.71%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
Health Care $36 Cleo Files Patents for its Ovarian Cancer Screening Test 30 Sep 2026 8:52AM $0.280 $0.260 fallen by 7.14%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
Health Care $36 CLEO Commences Ovarian Cancer Screening Test Development 24 Sep 2026 9:09AM $0.305 $0.260 fallen by 14.75%

COV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$5.94 -$4.50 43.70% 0.00 0.00 0.00% 0.0%
2025A -$4.00 -$3.10 -2.80% 0.00 0.00 0.00% 0.0%
2024A -$3.76 -$3.20 -51.40% 0.00 0.00 0.00% 0.0%

COV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Cochlear Limited (COH) $10,017M -0.3136 0.2540 0.0785 37.2903 29.7371 27.5729 2.25% 2.34% 2.55%
Cleo Diagnostics Ltd (COV) $37M 0.4373 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH) $23,213M 0.1388 0.1471 0.1573 59.6703 52.0169 44.9482 1.10% 1.19% 1.32%
Imricor Medical Systems Inc (IMR) $490M -0.4254 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
ResMed Inc. (RMD) $19,860M 9.5922 0.1126 0.0881 23.0505 20.7178 19.0410 1.01% 1.07% 1.15%

COV Directors

Name Position Start Date
Dr Richard Allman Chief Executive Officer, Managing Director 10 Oct 2022
Dr Andrew Nicholas Stephens Chief Scientific Officer, Executive Director 19 Sep 2022
Professor Thomas Jobling Lead Medical Advisor, Non-Executive Director 21 Dec 2022
Mr Adrien Michele Wing Non-Executive Chairman, Non-Executive Director 11 Aug 2022
Ms Lucinda Nolan Non-Executive Director 2 Mar 2023

Cleo Diagnostics Ltd (COV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
24 Aug 2026 JOBLING, Thomas Buy Indirect Shares 1,500,000 $0.300 $450,000.000
24 Aug 2026 NOLAN, Lucinda Buy Indirect Shares 1,500,000 $0.300 $450,000.000
24 Aug 2026 NOLAN, Lucinda Exercise Options 1,500,000 $0.300 $450,000.000

See all changes in directors' interest & trades for Cleo Diagnostics Ltd (COV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

COV Management

Name Position
Pauline M Moffatt Company Secretary

COV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cleo Diagnostics Ltd (COV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
14,250,000 (10.39%) Michelle Wing
8,446,312 (6.16%) Richard Vom

COV Calendar of Events

Date Event
19 August 2027 Report (Annual)
19 August 2027 Report (Prelim)
24 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.